AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

WILMINGTON, Del., March 30, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.:

  • Do you own shares of Auspex Pharmaceuticals, Inc. (NASDAQ GM: ASPX)?
  • Did you purchase any of your shares prior to March 30, 2015?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") (NASDAQ GM: ASPX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Teva Pharmaceuticals Industries Ltd. ("Teva") (NYSE: TEVA), in a transaction valued at approximately $3.5 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/auspex-pharmaceuticals-inc-aspx.   

Under the terms of the agreement, public shareholders of Auspex would receive $101.00 in cash for each share of Auspex they own.

The investigation concerns whether Auspex's board of directors failed to adequately shop the Company and obtain the best possible value for Auspex's shareholders before entering into an agreement with Teva.  According to Yahoo! Finance, at least one analyst has issued a price target for Auspex stock at $105.00 per share.

If you own the common stock of Auspex and purchased your shares before March 30, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to [email protected], or at: http://www.rigrodskylong.com/investigations/auspex-pharmaceuticals-inc-aspx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
[email protected] 
http://www.rigrodskylong.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/auspex-pharmaceuticals-inc-shareholder-alert-rigrodsky--long-pa-announces-investigation-of-buyout-300057598.html

SOURCE Rigrodsky & Long, P.A.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.